Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Novo Nordisk A/S — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.74, while Novo Nordisk A/S trades at $49.33 (market cap $216.71B). The key difference: Novo Nordisk A/S pays a 3.64% dividend while YieldMax AMZN Option Income Strategy ETF pays none, and Novo Nordisk A/S is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | NVO | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $16.61 | $71.70 |
52-Week Low | $10.26 | $35.29 |
Market Cap | — | $216.71B |
Enterprise Value | — | $235.67B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
Novo Nordisk (NVO) trades at $49.48, up 1.23% today, with a bullish technical signal from moving averages and strong fundamentals including a 37.2% net income margin and 71.4% ROE. Recent earnings beats in Q3 2025-Q1 2026 highlight operational strength, while cash flow remains positive at $10.81B in 2025. The stock benefits from GLP-1 drug leadership, with oral Wegovy driving market expansion amid competitive pressures.
Outlook is positive with analyst consensus at 57.9% buy ratings, but risks include prescription slowdown concerns and rising debt-to-asset ratio to 22.54 in 2025. Investment appeal lies in robust profitability and growth in obesity/diabetes treatments, though investors should monitor competition and execution on guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
